A COMPARISON OF PROGNOSTIC VARIABLES AND CYTOGENETIC ABERRATIONS IN 1590 PATIENTS WITH THERAPY-RELATED AND 4738 WITH PRIMARY MDS INCLUDING THE INFLUENCE OF TREATMENT IN MDS-PHASE
Andrea Kuendgen, Detlef Haase(Universitätsmedizin Göttingen), Rami S. Komrokji(Moffitt Cancer Center), Gail J. Roboz(Cornell University), Montserrat Martinez-De-Sola, Xavier Calvo(Hospital Del Mar), Maria López‐Pavía, Amy E. DeZern(Johns Hopkins University), Peter L. Greenberg(Stanford University), Aristoteles Giagounidis(Marien Hospital Düsseldorf), Sabine Blum(University of Lausanne), Michael Lübbert(University of Freiburg), Meritxell Nomdedéu(Hospital Clínic de Barcelona), Matteo Della Porta(University of Milan), Guillermo Sanz(Instituto de Salud Carlos III), Mikkael A. Sekeres(University of Miami), Sascha Dietrich(European Molecular Biology Organization), Guillermo Garcia‐Manero(The University of Texas MD Anderson Cancer Center), Julia Mestre, Javier Grau, María Díez‐Campelo(Complejo Hospitalario de Salamanca), Ulrich Germing(Düsseldorf University Hospital), Maria Teresa Voso(University of Rome Tor Vergata), Blanca Xicoy(Hospital Universitari Germans Trias i Pujol), Heinz Tuechler, Esperanza Such(Leitat Technological Center), Luca Malcovati(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Marina Díaz‐Beyá(Hospital Clínic de Barcelona), Benet Nomdedeu, Uwe Platzbecker(National Center for Tumor Diseases), Corinna Strupp(Heinrich Heine University Düsseldorf), Christina Ganster(Universitätsmedizin Göttingen), Arjan van de Loosdrecht(Amsterdam University Medical Centers), Françesc Solé(Fundación Josep Carreras Contra la Leucemia), Oriol Calvete(Spanish National Cancer Research Centre), Leonor Arenillas(Hospital Del Mar), Hartmut Döhner(University Hospital Ulm), Barbara Hildebrandt(Heinrich Heine University Düsseldorf), Itziar Oiartzabal, Costa Dolors, Maria Teresa Diez-Cedena, Esteve Jordi, Peter Valent(Medical University of Vienna)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k